Longeveron, Inc. announced the activation of two new clinical sites for the currently enrolling ELPIS II Trial, evaluating Lomecel-B injection into the myocardium of infants with Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect.
[Longeveron, Inc.]
Sorry, but the selected Zotpress account can't be found.
